Bladder17™

Developing the most sensitive and specific bladder cancer test

Brochure

About the Bladder17™ bladder cancer test

Bladder cancer is one of the major cancers of the urinary system that is one of the most expensive cancers to treat due to a high recurrence rate.

Cystoscopy is often augmented by a non-invasive laboratory method such as urine cytology. Bladder17 provides sensitivity and specificity to significantly improve the diagnosis and treatment of bladder cancer patients,

Sample Report

Download PDF

Find Out More (Patients)Find Out More (PHysicians)

Bladder17™ - For Physicians

Current Detection Methods

The current gold standard for bladder cancer detection is cystoscopy.
Cystoscopy is a painful and invasive procedure performed by a urologist
Confirmatory tests such as a CT Scan, intravenous, pyelogram (IVP), X-Ray, MRI, Ultra-sound, and urine cytology are also used but with limited utility.

Bladder17™

Collect Urine Sample
Send to EmeritusDX
Discuss Results With Your Patient

SENSITIVE AND SPECIFIC: 100% Sensitivity & 96% Specificity*

COMPATIBLE: With all standard immunohistochemistry systems

GOLD STANDARD POTENTIAL: Current data suggests Bladder17™ test is the most sensitive/specific for bladder cancer test

Publications

1- Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia (pdf)

Download

2-Vasdev et al-2020BJUI Com Published Paper 102620 (pdf)

Download

3- K17 as a cytologic biomarker-AJCP-2021- 2nd paper 060821 (pdf)

Download

Privacy Notice
Healthcare Disclaimer

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Decline Accept